Literature DB >> 21595781

Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study.

J Yue1, Y Yang, A R Cabrera, X Sun, S Zhao, P Xie, J Zheng, L Ma, Z Fu, J Yu.   

Abstract

The purpose of this study was to evaluate hypoxia in esophageal squamous cell carcinoma (SCC) with (18)F-fluoroerythronitroimidazole positron emission tomography/computed tomography ((18)F-FETNIM PET/CT). We determined an imaging threshold for hypoxia, quantified the spatiotemporal variability of hypoxia in untreated tumor, and evaluated the ability of (18)F-FETNIM PET to predict clinical response following concurrent chemoradiotherapy (CCRT). Twenty-eight consecutive patients with inoperable SCC of the esophagus were consecutively accrued between April 2007 and June 2010. The first 10 patients received two pretreatment (18)F-FETNIM PET/CT scans on separate days. The remaining 18 patients only underwent (18)F-FETNIM PET/CT once before CCRT. The ratio of the maximum standardized uptake value (SUV(max) ) of 336 normal tissue regions (i.e. heart, lung, brain, or muscle) to the mean standardized uptake value (SUV(mean)) of the respective patient's spleen was calculated, and the imaging threshold for hypoxia defined as the level of uptake demonstrated by less than 5% of tissue regions. Among the patients with two pretreatment scans, each pair of scans was compared with respect to location and intensity of uptake to assess for baseline spatiotemporal variability. Logistic regression analysis was used to determine whether pretreatment imaging characteristics are predictive of clinical response. The mean and median ratios of the SUV(max) of tissue : SUV(mean) of spleen were nearly identical, and 95% of the ratios fell below 1.3. The mean Dice similarity coefficient for the hypoxic volumes on pretreatment PET scans acquired in the same patient on different days was 0.12 (range, 0.05-0.21). Individuals' tumor SUV(max) and SUV(mean) did not vary significantly, but on average, the geometric centers of hypoxic regions shifted 15 mm (range, 8-20 mm) from the first pretreatment scan to the second. SUV(max) was the imaging characteristic most predictive of treatment response (P= 0.041), with high SUVmax associated with poor clinical response. (18)F-FETNIM PET/CT can depict hypoxia in esophageal SCC. Prior to CCRT, tumor hypoxia demonstrates spatial variability on different days, although overall (18)F-FETNIM uptake remains similar. Baseline SUV(max) may be predictive of treatment response.
© 2011 Copyright the Authors. Journal compilation © 2011, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595781     DOI: 10.1111/j.1442-2050.2011.01209.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  17 in total

1.  Correlation of hypoxia as measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM) PET/CT and overall survival in glioma patients.

Authors:  Man Hu; Yufang Zhu; Dianbin Mu; Bingjie Fan; Shuqiang Zhao; Guoren Yang; Li Ma; Jinsong Zheng; Jinming Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-28       Impact factor: 9.236

Review 2.  Imaging hypoxia to improve radiotherapy outcome.

Authors:  Michael R Horsman; Lise Saksø Mortensen; Jørgen B Petersen; Morten Busk; Jens Overgaard
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

Review 3.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

Review 4.  Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.

Authors:  Sonja Stieb; Afroditi Eleftheriou; Geoffrey Warnock; Matthias Guckenberger; Oliver Riesterer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-20       Impact factor: 9.236

Review 5.  Optimizing hypoxia detection and treatment strategies.

Authors:  Cameron J Koch; Sydney M Evans
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

Review 6.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 7.  Imaging tumour hypoxia with positron emission tomography.

Authors:  I N Fleming; R Manavaki; P J Blower; C West; K J Williams; A L Harris; J Domarkas; S Lord; C Baldry; F J Gilbert
Journal:  Br J Cancer       Date:  2014-12-16       Impact factor: 7.640

Review 8.  Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers.

Authors:  Ross King; Conall Hayes; Claire L Donohoe; Margaret R Dunne; Maria Davern; Noel E Donlon
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

9.  Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer.

Authors:  Joseph A O'Donoghue; José G Guillem; Heiko Schöder; Nancy Y Lee; Chaitanya R Divgi; Jeannine A Ruby; John L Humm; Steven A Lee-Kong; Eva M Burnazi; Shangde Cai; Sean D Carlin; Tobias Leibold; Pat B Zanzonico; C Clifton Ling
Journal:  EJNMMI Res       Date:  2013-06-03       Impact factor: 3.138

Review 10.  The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies.

Authors:  J M Wilson; M Partridge; M Hawkins
Journal:  Clin Oncol (R Coll Radiol)       Date:  2014-07-04       Impact factor: 4.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.